Brigatinib Bei ALK-positivem NSCLC

Im Focus Onkologie
doi 10.1007/s15015-017-3548-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy